The FDA today published a formal proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, citing a finding of “no clinical need” for outsourcing facilities to compound these substances from bulk active pharmaceutical ingredient. The proposal codifies the end of large-scale GLP-1 compounding by 503B outsourcing facilities and is the most consequential GLP-1 compounding action since the FDA resolved the underlying drug shortages in 2024 and 2025. Public comment is open through June 30, 2026, before the FDA finalizes the determination. (FDA press announcement; Federal Register docket 2026-08552)

The proposal does several specific things and does not do several others. The distinction matters, and most consumer coverage in the first 24 hours is conflating the two.

What This Proposal Does

The 503B bulks list is a regulatory tool that identifies bulk drug substances that outsourcing facilities (large-scale pharmacies registered as 503B facilities under the Federal Food, Drug, and Cosmetic Act) may use to compound medications. In most cases, a 503B facility cannot compound from a bulk substance unless that substance appears on the bulks list, or the compounded drug is on the FDA’s drug shortage list.

Tirzepatide was on the drug shortage list until December 2024. Semaglutide was on the shortage list until February 2025. Liraglutide is not currently on the shortage list. Once those shortages were resolved, the legal pathway that allowed outsourcing facilities to compound these GLP-1s closed—except to the extent the substances were nominated for inclusion on the 503B bulks list.

Today’s proposal is the FDA’s response to those nominations. The agency reviewed the submissions, applied the 503B clinical-need framework, and concluded there is not sufficient evidence to include any of the three substances. If the proposal is finalized as drafted after the June 30 comment deadline, semaglutide, tirzepatide, and liraglutide will be formally excluded from the bulks list, closing the second of the two pathways that allowed 503B-scale compounding of these drugs.

What This Proposal Does Not Do

This is the part that most consumer coverage is misreading.

The proposal does not affect 503A pharmacies. 503A facilities are state-licensed compounding pharmacies that prepare patient-specific prescriptions—a different regulatory category, governed by different rules, with different rights to compound from bulk substances. The 503A pathway is not addressed in today’s proposal. Patients who currently obtain compounded semaglutide from a 503A pharmacy under physician prescription would not be affected by this rule.

The proposal does not ban compounding of these GLP-1 drugs in all forms. Patient-specific compounding under the 503A pathway, when consistent with state law and FDA enforcement priorities, remains a separate question. The proposal narrows—but does not close—the legal universe of compounded GLP-1 access.

The proposal does not take immediate effect. The 60-day comment period through June 30 must run, then the FDA must review comments, then the agency must finalize the determination. The earliest the proposal could become effective is several months from now, depending on the comment volume and the FDA’s response timeline.

The proposal does not reflect a safety determination against GLP-1 drugs themselves. It reflects a regulatory finding under the specific 503B clinical-need framework, which evaluates whether outsourcing facilities should be permitted to compound from bulk substances given current drug supply, manufacturing standards, and patient access pathways. The finding is a regulatory judgment about compounding, not a clinical judgment about the underlying drugs.

Why the FDA Is Proposing This

The proposal articulates several rationales, drawn from the agency’s evaluation of public comments and quality data accumulated during the shortage period.

The drugs are no longer in shortage. The original justification for compounded GLP-1s—patient access during shortage of the FDA-approved branded drugs—is no longer present. With Mounjaro, Zepbound, Ozempic, Wegovy, and the now-approved Foundayo (orforglipron) all available through commercial supply chains, the FDA’s position is that compounding from bulk substances is not a necessary access mechanism for these treatments.

Compounded GLP-1s have generated significant adverse event reports during the shortage period. The Partnership for Safe Medicines and other advocacy groups have cited “hundreds of adverse events—including sepsis, liver injury, and hospitalizations—as well as recalls involving thousands of contaminated or improperly dosed vials.” These are real safety signals associated specifically with mass-compounded products, distinct from the safety profile of the FDA-approved branded drugs.

503B outsourcing facilities operate at industrial scale, which the FDA has consistently treated as a higher-risk compounding category requiring stronger justification. The “clinical need” framework that governs 503B inclusion was designed to allow compounding when patient access can’t be met through approved drugs—a condition that no longer applies for these GLP-1s.

What’s Likely to Happen in the Comment Period

The June 30 comment deadline will see organized advocacy on both sides. Patient-safety groups are positioned to support the exclusion; the Partnership for Safe Medicines has already publicly endorsed it. Compounding industry groups are likely to oppose, though the early signal from the Alliance for Pharmacy Compounding has been that the proposal “does not change the status quo”—a measured framing that suggests the industry may direct its primary advocacy energy toward preserving the 503A pathway rather than fighting the 503B exclusion head-on.

Telehealth providers that have built business around compounded GLP-1s—Hims & Hers prominently among them—have already begun pivoting toward FDA-approved branded products, suggesting the commercial channel is internally adapting to the regulatory direction even before the rule is final.

Members of Congress who have spoken on peptide and compounding policy may engage. The space is politically active, and patient testimony arguing that compounded GLP-1s remain a meaningful access mechanism—particularly for patients without insurance coverage for the branded products—will likely appear in the docket.

The most likely outcome is finalization with limited substantive changes from the proposed version. The FDA’s reasoning is well-established under the existing 503B clinical-need framework, and the agency rarely reverses a “no clinical need” finding once published. What may shift in the final version is the implementation timeline and any transition guidance for outsourcing facilities currently producing these substances.

What This Means for Peptidings Readers

For patients on FDA-approved Mounjaro, Zepbound, Ozempic, Wegovy, or Foundayo, this proposal changes nothing. Those products are not affected.

For patients currently obtaining compounded GLP-1s through a 503A pharmacy under physician prescription, this proposal does not affect that pathway directly. The 503A question is a separate and ongoing one.

For patients obtaining compounded GLP-1s through telehealth channels that source from 503B facilities, the practical landscape is going to narrow over the next 12 months—both through this regulatory action and through commercial decisions already being made by major telehealth providers.

The broader regulatory direction is clear. The window for large-scale compounding of FDA-approved drugs that are no longer in shortage is closing. Patient access to GLP-1 drugs going forward will increasingly depend on the FDA-approved branded products, insurance coverage, and the patient-specific 503A pathway—not on the 503B compounding lanes that filled the gap during the 2023–2025 shortage period.

Peptidings will cover the comment period, the final rule, and any subsequent enforcement actions. Our compounding categories explainer walks through the 503A versus 503B distinction in greater detail, and a forthcoming Behind the Evidence column will dig into what the regulatory and clinical-need frameworks actually require and what the next round of compounding fights are likely to look like.

References

1. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. FDA press announcement. April 30, 2026. FDA
2. List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B. Federal Register. May 1, 2026. Docket 2026-08552. Federal Register
3. FDA Moves to Permanently Close the Door on Compounded GLP-1s. Pharmacy Times. 2026. Pharmacy Times
4. FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs. Orrick. May 2026. Orrick
5. FDA Signals it Has No Appetite to Add Popular GLP-1 Drug Substances to the 503B Bulks List. National Law Review. 2026. National Law Review